Bisphosphonates Might Get Limits On Treatment Duration Following Label Change
This article was originally published in The Pink Sheet Daily
Executive Summary
Accumulating data on femur fractures lead FDA to consider telling physicians to take patients off the drug at least temporarily when bone mineral density targets are reached.
You may also be interested in...
Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee
FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."
Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee
FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."
Genentech Fields Overstated Claim For Boniva, DDMAC Says
The ad for the osteoporosis drug - featuring actress Sally Field and running in Parade magazine - was improperly based on a post-hoc responder analysis, DDMAC says.